OST11098 / Open Source Therapeutics - LARVOL DELTA

OST11098, an orally available and selective Cyp11A1 inhibitor for the treatment of castration-resistant prostate cancer (CRPC) with next-generation hormone agents (NHAs) resistance (AACR 2025) - "Next-generation hormone agents (NHAs) such as abiraterone and enzalutamide have become standard treatments for castration-resistant prostate cancer (CRPC), significantly prolonging patient survival. Moreover, an engineered LNCaP CRPC xenograft mouse model with NHA resistance was successfully established and evaluated for its response to OST11098 treatment, providing compelling preclinical evidence supporting the use of CYP11A1 inhibitors as a promising strategy for managing NHA-resistance.Overall, our studies demonstrated OST11098 as a highly potent and selective CYP11A1 inhibitor with great PK properties, clean safety profiles, and significant anti-tumor activity for the treatment of CRPC. These promising preclinical results strongly support the potential of OST11098 to address unmet needs in CRPC treatment, justifying its further clinical development."

Adrenal Cortex Carcinoma • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor